Moderna Inc. and Merck & Co. reported on Wednesday that their personalized mRNA cancer vaccine, when combined with Merck's immunotherapy drug Keytruda, successfully reduced the recurrence and spread of melanoma in a large, late-stage clinical trial. This marks a significant milestone for mRNA-based therapies in oncology, with the trial meeting its primary goal of lowering the rate of melanoma recurrence compared to Keytruda alone. The study also achieved a key secondary objective by demonstrating the vaccine's ability to help prevent tumors from spreading to other parts of the body.
The news triggered a substantial market reaction. Moderna's stock soared, with some reports indicating a surge of up to 177% to $174.38, reflecting renewed investor confidence in the company's prospects beyond its COVID-19 vaccine. Merck's shares also saw an uplift, with one report noting a 12% jump. This success is seen as a pivotal moment for cancer research, showcasing the potential of personalized mRNA treatments.
Analysts are optimistic about the therapy's commercial potential. Barclays, for instance, estimates that this combination therapy could generate approximately $3 billion in melanoma sales by 2035. The positive outcomes underscore the revival of hopes for mRNA technology in cancer treatment and positions Moderna as a significant player in drug development, moving beyond its initial success in infectious diseases.
